共 23 条
- [3] Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (06) : 661 - 673
- [4] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
- [5] Connolly LE, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01989-17, 10.1128/aac.01989-17]
- [9] Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/cir102, 10.1093/cid/ciq257]
- [10] Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (08): : 788 - 799